336 related articles for article (PubMed ID: 11921435)
1. Differentiating members of the thiazolidinedione class: a focus on safety.
Lebovitz HE
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
[TBL] [Abstract][Full Text] [Related]
2. Differentiating members of the thiazolidinedione class: a focus on efficacy.
Goldstein BJ
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S16-22. PubMed ID: 11921434
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
4. Are all glitazones the same?
Van Gaal L; Scheen AJ
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431
[TBL] [Abstract][Full Text] [Related]
5. [Thiazolidinediones: clinical data and perspectives].
Blicklé JF
Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
Parker JC
Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
Gegick CG; Altheimer MD
Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
[TBL] [Abstract][Full Text] [Related]
9. The glitazones: proceed with caution.
Krische D
West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
[No Abstract] [Full Text] [Related]
10. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
11. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
King AB
Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
[No Abstract] [Full Text] [Related]
12. How should patients taking the discontinued diabetes drug troglitazone be managed?
Reddy SS
Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
[No Abstract] [Full Text] [Related]
13. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
15. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Malinowski JM; Bolesta S
Clin Ther; 2000 Oct; 22(10):1151-68; discussion 1149-50. PubMed ID: 11110228
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
[No Abstract] [Full Text] [Related]
18. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Samraj GP; Kuritzky L; Quillen DM
Hosp Pract (1995); 2000 Jan; 35(1):123-4, 129-32. PubMed ID: 10645993
[No Abstract] [Full Text] [Related]
19. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
